Ccrcc clinical trials

Explore recruiting ccrcc clinical trials.

Recruiting ccrcc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Ccrcc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

EORTC-2361-GUCG: Phase II trial evaluating the efficacy of 177Lutetium-PSMA treatment in patients with metastatic clear cell Renal Carcinoma Cell with progressive disease on first-line or second-line systemic treatment (RENALUT)

Spain, France, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/1b First-in-Human Study of BMS-986506 in ccRCC

Spain, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants with Advanced/Metastatic Solid Tumors

Italy, France, Belgium, Spain, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Open-label, Randomized, Phase 1/2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan Monotherapy in Participants with Advanced Renal Cell Carcinoma

Sweden, Poland, France, Germany, Italy, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)

Hungary, Finland, Sweden, Netherlands, Ireland, Spain +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Germany, France, Denmark, Sweden, Finland, Romania +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Ccrcc trials by city

Ccrcc in Toronto Ccrcc in Vancouver Ccrcc in Montreal Ccrcc in Calgary Ccrcc in Edmonton Ccrcc in Ottawa Ccrcc in Winnipeg Ccrcc in Quebec City Ccrcc in Hamilton Ccrcc in Kitchener Ccrcc in London Ccrcc in Halifax Ccrcc in New York Ccrcc in Los Angeles Ccrcc in Chicago Ccrcc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease